Effects of human ERMAP-siRNA on erythroid differentiation of K562 cells induced by Ara-C.
- Author:
Jie-Fang LIANG
1
;
Ying CHEN
;
Tie-Zhen YE
;
Ying-Yi HE
;
Xin-Rong HE
;
Li-Dan LIN
;
Sai-Jun GAO
Author Information
1. Department of Hematology and Oncology, Medical Health Center for Women and Children, Guangzhou 510120, Guangdong Province, China.
- Publication Type:Journal Article
- MeSH:
Blood Group Antigens;
genetics;
Butyrophilins;
Cell Differentiation;
drug effects;
Cytarabine;
pharmacology;
Erythropoiesis;
drug effects;
Humans;
K562 Cells;
RNA, Messenger;
RNA, Small Interfering;
pharmacology
- From:
Journal of Experimental Hematology
2009;17(1):49-53
- CountryChina
- Language:Chinese
-
Abstract:
In order to investigate the potential role of human ERMAP gene in erythropoiesis, the ERMAP-dsDNA was designed, ERMAP-shRNA expressing plasmids was constructed, and ERMAP-shRNA/K562 cell was established. Cell morphology, biphenylamine staining, expression of cell surface antigens as well as quantitative level of human ERMAP gene were observed during K562 cells differentiating toward erythroid lineage induced by Ara-C. The results showed that at 72 hours after Ara-C treatment, ERMAP-shRNA/K562 cell size became large with increasing cytoplasm content. The percentage of biphenylamine positive cells increased from 1.17% to 2.04% (p < 0.05), but still lower than that in group K562 + Ara-C. The percentage of CD36(-)/CD235a(+) increased from 8.83% to 11.28%, CD36(+)/CD235a(+) increased from 1.23% to 2.64%, and CD36(+)/CD235a(-) increased from 0.59% to 1.47% respectively, which were all lower than that in group K562 + Ara-C at either time point. At the same time, the level of ERMAP expression increased slowly from 2.52 x 10(-3) to 4.53 x 10(-3), which was also significantly lower than that of group K562 + Ara-C. It is concluded that the ERMAP-shRNA inhibits the Ara-C-induced erythroid differentiation of K562 cells, which further suggests that there is relationship between hERMAP and erythroid differentiation and development.
